KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Vertex Pharmaceuticals (VRTX) EBT Margin (2016 - 2025)

Historic EBT Margin for Vertex Pharmaceuticals (VRTX) over the last 17 years, with Q3 2025 value amounting to 42.22%.

  • Vertex Pharmaceuticals' EBT Margin fell 19400.0% to 42.22% in Q3 2025 from the same period last year, while for Sep 2025 it was 37.95%, marking a year-over-year increase of 355000.0%. This contributed to the annual value of 2.25% for FY2024, which is 421200.0% down from last year.
  • As of Q3 2025, Vertex Pharmaceuticals' EBT Margin stood at 42.22%, which was down 19400.0% from 43.28% recorded in Q2 2025.
  • Vertex Pharmaceuticals' 5-year EBT Margin high stood at 54.57% for Q3 2021, and its period low was 128.18% during Q2 2024.
  • Its 5-year average for EBT Margin is 32.77%, with a median of 45.52% in 2022.
  • In the last 5 years, Vertex Pharmaceuticals' EBT Margin plummeted by -1747700bps in 2024 and then surged by 1714600bps in 2025.
  • Quarter analysis of 5 years shows Vertex Pharmaceuticals' EBT Margin stood at 42.02% in 2021, then increased by 11bps to 46.76% in 2022, then fell by -3bps to 45.58% in 2023, then fell by -14bps to 39.03% in 2024, then increased by 8bps to 42.22% in 2025.
  • Its EBT Margin was 42.22% in Q3 2025, compared to 43.28% in Q2 2025 and 26.37% in Q1 2025.